| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443746 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
Brostallicin cannot be recommended at this dose and schedule in this patient population as first-line therapy. GSTA1 genotype may be predictive for doxorubicin efficacy but warrants further study.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
H. Gelderblom, J.Y. Blay, B.M. Seddon, M. Leahy, I. Ray-Coquard, S. Sleijfer, J.M. Kerst, P. Rutkowski, S. Bauer, M. Ouali, S. Marreaud, R.J.H.M. van der Straaten, H.-J. Guchelaar, S.D. Weitman, P.C.W. Hogendoorn, P. Hohenberger,